It has been confirmed from both in vitro and in vivo studies that hybridoma cell line development secretes antibodies that are specific and exhibit high affinity for antigen IL13Rα2-associated with tumors and thus provides a novel therapeutic strategy for glioblastoma (Balyasnikova et al., 2012). Here, IL13RA2 is linked to glioblastoma.